Connect with us

Business

Tesla set to begin deliveries of China-made Model 3 cars

Published

 on

U.S. electric vehicle maker Tesla Inc will begin delivering Model 3 vehicles built at its Shanghai factory on Monday, a company representative told Reuters.

Construction of its first plant outside the United States began in January and production started in October. It aims to produce 250,000 vehicles a year after production of the Model Y is added in the initial phase.

The first 15 customers to get the cars on Dec 30 are Tesla employees, the company representative added.

The delivery date of Dec. 30 means that the plant will start delivering cars to customers just 357 days after the factory’s construction started, which will mark a new record for global automakers in China.

The China-made cars are priced at 355,800 yuan ($50,000) before subsidies and Tesla has said it wants to start deliveries before Chinese new year beginning on Jan. 25.

The Shanghai plant is part of the Silicon Valley automaker’s plans to bolster its presence in the world’s biggest auto market and minimize the impact of the U.S.-China trade war.

The car maker already treats China, the world’s biggest electric vehicle market where 1.3 million new-energy vehicles were sold last year, differently than elsewhere, with offerings such as racing events and showroom parties.

It is also building service centres and charging stations across China to assure customers of standardized after-sales service, Reuters reported last month.

The Chinese government has also been supportive of the factory, which is China’s first wholly foreign-owned car plant and a reflection of the government’s broader shift to open up its car market.

The Ministry of Industry and Information Technology on Friday said it had added Tesla’s China-made Model 3 to a list of new energy vehicles exempt from purchase tax.

The ministry had said in August it had exempted all of Tesla’s models from purchase tax.

Source link

Business

What supply chain shortages look like for two Canadians – CBC.ca

Published

 on


[unable to retrieve full-text content]

  1. What supply chain shortages look like for two Canadians  CBC.ca
  2. Canadian ski resorts struggle to hire enough workers ahead of season  CBC.ca
  3. Calls to end ‘hybrid’ classrooms in Ontario with in-person and virtual teaching  CBC.ca
  4. A life story told in outfits: Anahid Chujunian discovers her voice one thrift find at a time  CBC.ca
  5. Amateur astronomer in Dartmouth has an asteroid named after him  CBC.ca
  6. View Full coverage on Google News



Source link

Continue Reading

Business

FDA says kid-sized Pfizer vaccine doses appear highly effective, safe – CBC.ca

Published

 on


U.S. health regulators said late Friday that kid-size doses of Pfizer’s COVID-19 vaccine appear highly effective at preventing symptomatic infections in elementary school children and caused no unexpected safety issues, as the country weighs beginning vaccinations in youngsters.

The Food and Drug Administration posted its analysis of Pfizer’s data ahead of a public meeting next week to debate whether the shots are ready for the nation’s roughly 28 million children ages 5 to 11. The agency will ask a panel of outside vaccine experts to vote on that question.

In their analysis, FDA scientists concluded that in almost every scenario the vaccine’s benefit for preventing hospitalizations and death from COVID-19 would outweigh any serious potential side effects in children. But agency reviewers stopped short of calling for Pfizer’s shot to be authorized.

The agency will put that question to its panel of independent advisers next Tuesday and weigh their advice before making its own decision.

U.S. children could begin vaccinations next month

If the FDA authorizes the shots, the Centers for Disease Control and Prevention will make additional recommendations on who should receive them the first week of November. Children could begin vaccinations early next month — with the first youngsters in line fully protected by Christmas.

Full-strength Pfizer shots already are recommended for anyone 12 or older, but pediatricians and many parents are anxiously awaiting protection for younger children to stem infections from the extra-contagious delta variant and help keep kids in school.

WATCH | Pfizer releases clinical trial data for COVID-19 vaccine for children aged 5 to 11:

Pfizer releases clinical trial data for COVID-19 vaccine for children aged 5 to 11

13 hours ago

Pfizer publicly released data from its coronavirus vaccine trial appearing to show that it’s both safe and effective for children aged five to 11. But that data is now being reviewed by regulators, and parents want to carefully weigh the risks. 2:03

The FDA review affirmed results from Pfizer posted earlier in the day showing the two-dose shot was nearly 91 per cent effective at preventing symptomatic infection in young children. Researchers calculated the figure based on 16 COVID-19 cases in youngsters given dummy shots versus three cases among vaccinated children. There were no severe illnesses reported among any of the youngsters, but the vaccinated ones had much milder symptoms than their unvaccinated counterparts.

Most of the study data was collected in the U.S. during August and September, when the delta variant had become the dominant COVID-19 strain.

No new side effects

The FDA review found no new or unexpected side effects, which mostly consisted of sore arms, fever or achiness that teens experience.

However, FDA scientists noted that the study wasn’t large enough to detect extremely rare side effects, including myocarditis, a type of heart inflammation that occasionally occurs after the second dose.

The agency used statistical modelling to try to predict how many hospitalizations and deaths from COVID-19 the vaccine would prevent versus the number of potential heart side effects it might cause. In four scenarios of the pandemic, the vaccine clearly prevented more hospitalizations than would be expected from the heart side effect. Only when virus cases were extremely low would the vaccine cause more hospitalizations than it would prevent. But overall, regulators concluded that the vaccine’s protective benefits “would clearly outweigh” its risks.

While children run a lower risk of severe illness or death than older people, COVID-19 has killed more than 630 Americans 18 and under, according to the CDC. Nearly 6.2 million children have been infected with the coronavirus, more than 1.1 million in the last six weeks as the delta variant surged, the American Academy of Pediatrics says.

The Biden administration has purchased enough kid-size doses — in special orange-capped vials to distinguish them from adult vaccine — for the nation’s 5- to 11-year-olds. If the vaccine is cleared, millions of doses will be promptly shipped around the country, along with kid-size needles.

More than 25,000 pediatricians and primary care providers already have signed up to get the shots into little arms.

Adblock test (Why?)



Source link

Continue Reading

Business

Edward Rogers’ role as Blue Jays chair unchanged amid changes atop RCI – Sportsnet.ca

Published

 on


TORONTO — Edward Rogers’ roles as chair of the Toronto Blue Jays and control person with Major League Baseball are unaffected by this week’s manoeuvrings that led to his removal as board chair of parent company Rogers Communications Inc., according to two industry sources.

Whether fallout from the power struggle atop the telecom giant, which also owns Sportsnet, might eventually reach the club is unclear. Last week, Blue Jays president and CEO Mark Shapiro said the team was “about a month away” from presenting its off-season plan during a final payroll meeting with ownership, and expressed confidence that its long-term strategic objectives would remain on track.

“Every indication I’ve received and every indication that we’ve been shown … leads me to believe that we will stay on plan and the payroll will continue to rise despite the fact that we’re still lagging behind a little bit in revenues due to (the pandemic),” Shapiro said.

Those comments came before news broke that John MacDonald, a member of the Rogers Board of Directors since 2012, had assumed the chairman role in place of Edward Rogers, who according to media reports had sought to oust company CEO Joe Natale.

Edward Rogers is now seeking to replace five board members.

At this point, the sources said the developments aren’t expected to impact a winter of opportunity for the Blue Jays, who are seeking to augment a club that missed the post-season by one game and are about to see top performers Marcus Semien, Robbie Ray and Steven Matz hit free agency.

Shapiro is close with Edward Rogers, who as chair is the top officer of the club. He is also the control person, a role each of the 30 MLB teams assigns to represent the interests of that ownership.

Adblock test (Why?)



Source link

Continue Reading

Trending